Interleukin-3 side effects: what 359 FDA adverse event reports show

Interleukin-3 · Guna-Il 3 · 8 reaction terms · 61 drug–reaction co-reports · data 2026-09-14

Drug class

Not stated in label

Brand names

Guna-Il 3

openFDA label

Who reports

359 reports · 91% serious · 56 with death outcome · 35% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Take 15 minutes before meals.

FDA label, Indications and Usage

Boxed warning

None in the current label

How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 8 strongest signals

Lab value / disease marker 1No label text to screen 7

What the badges mean

Lab value / disease marker A laboratory result, investigation or disease-activity marker (antibody positive, CRP abnormal, swollen joint count) not described in the label. These usually mirror the monitored disease or testing protocol rather than a drug effect; not screened further.
Not in label — unassessed Not found in the label text, not an artifact pattern. This is a genuine candidate for a formal causality assessment (Bradford Hill / WHO-UMC); it has NOT had one here.
No label text to screen No validated FDA label was retrievable for this product, so the screen could not run. Disproportionality only.

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only and flags pairs whose reports are unusually skewed by sex or come mostly from consumers rather than clinicians. 0 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show: hide coding/lab/outcome terms hide indication terms unlabeled only hide PRR-only

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Metastases to lung	10	50.6 27.5–93.3ROR 52.1 · χ² 438 / p 1e-97	46.4 EB05 26.9 · IC025 +2.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 25.7	no trial data cached
Bone marrow failure	12	34.3 19.6–59.8ROR 35.4 · χ² 355 / p 2e-79	32.6 EB05 19.9 · IC025 +2.9 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 21.7	no trial data cached
Ejection fraction decreased	9	33.8 17.7–64.4ROR 34.6 · χ² 254 / p 1e-57	31.6 EB05 17.7 · IC025 +2.5 3/3 methods agree	Lab value / disease marker	serious PRR 20.8	no trial data cached
Proteinuria	8	24.8 12.5–49.2ROR 25.3 · χ² 160 / p 7e-37	23.0 EB05 11.7 · IC025 +2.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 17.5	no trial data cached
Metastases to liver	7	23.3 11.2–48.6ROR 23.8 · χ² 128 / p 5e-30	21.1 EB05 9.5 · IC025 +1.9 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 10.6	no trial data cached
Metastases to central nervous system	5	22.8 9.5–54.5ROR 23.1 · χ² 84 / p 3e-20	18.7 EB05 6.0 · IC025 +1.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 11.6	no trial data cached
Metastases to bone	5	17.9 7.5–42.6ROR 18.1 · χ² 64 / p 8e-16	13.4 EB05 4.4 · IC025 +1.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 9.1	no trial data cached
Osteonecrosis of jaw (jawbone death)	5	11.7 4.9–28.0ROR 11.9 · χ² 39 / p 2e-10	7.6 EB05 3.0 · IC025 +1.0 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 7.4	no trial data cached

Trial evidence (ClinicalTrials.gov)

Trial cross-check not yet run for this drug (ClinicalTrials.gov pull covers the 800 most-reported drugs first).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

Reaction	Reports	PRR 95% CI · ROR · χ²/p	EBGM EB05 · IC025	Label screen	Serious-only & strata	Trial cross-check
Bone marrow failure	12	34.3 19.6–59.8ROR 35.4 · χ² 355 / p 2e-79	32.6 EB05 19.9 · IC025 +2.9 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 21.7	no trial data cached
Metastases to lung	10	50.6 27.5–93.3ROR 52.1 · χ² 438 / p 1e-97	46.4 EB05 26.9 · IC025 +2.8 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 25.7	no trial data cached
Ejection fraction decreased	9	33.8 17.7–64.4ROR 34.6 · χ² 254 / p 1e-57	31.6 EB05 17.7 · IC025 +2.5 3/3 methods agree	Lab value / disease marker	serious PRR 20.8	no trial data cached
Proteinuria	8	24.8 12.5–49.2ROR 25.3 · χ² 160 / p 7e-37	23.0 EB05 11.7 · IC025 +2.2 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 17.5	no trial data cached
Metastases to liver	7	23.3 11.2–48.6ROR 23.8 · χ² 128 / p 5e-30	21.1 EB05 9.5 · IC025 +1.9 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 10.6	no trial data cached
Osteonecrosis of jaw (jawbone death)	5	11.7 4.9–28.0ROR 11.9 · χ² 39 / p 2e-10	7.6 EB05 3.0 · IC025 +1.0 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 7.4	no trial data cached
Metastases to bone	5	17.9 7.5–42.6ROR 18.1 · χ² 64 / p 8e-16	13.4 EB05 4.4 · IC025 +1.3 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 9.1	no trial data cached
Metastases to central nervous system	5	22.8 9.5–54.5ROR 23.1 · χ² 84 / p 3e-20	18.7 EB05 6.0 · IC025 +1.4 3/3 methods agree	No label text to screen label has no adverse-reaction text	serious PRR 11.6	no trial data cached

Unlabeled candidate signals

Every screened signal with n ≥ 20 was either labeled, an indication term, or an artifact pattern — no unlabeled candidate stood out in the top signals.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Interleukin-3?

In FDA FAERS, the most frequently co-reported reaction terms for Interleukin-3 are bone marrow failure, metastases to lung, ejection fraction decreased, proteinuria, metastases to liver, osteonecrosis of jaw. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Interleukin-3 have an FDA boxed warning?

No. The FDA label retrieved for Interleukin-3 has no boxed warning; see the label's Warnings and Precautions for the recognised risks.

Do FAERS signals prove that Interleukin-3 causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

FDA label via openFDA (set ID 5be3096f-9046-457c-b7ba-767ffe74c07a, effective 20221115; matched on openfda.generic_name.exact:"INTERLEUKIN-3")
Bayesian shrinkage measures computed offline over all 1,317,300 cached pairs: BCPNN information component (IC, with Norén closed-form IC025) and MGPS empirical-Bayes geometric mean (EBGM, EB05) with a two-component gamma prior fitted by maximum marginal likelihood (α₁=0.57, β₁=0.02, α₂=1.42, β₂=0.70, w=0.17); unstratified
FAERS pair statistics from the OpenPV build of 2026-09-14 (openFDA count= aggregation, field patient.drug.openfda.generic_name.exact, 8 reaction terms, min 3 co-reports); PRR/ROR with 95% CI, chi-square with Yates correction
Serious-only and stratified counts (serious:1, patient.patientsex, primarysource.qualification) from openFDA count queries; serious-only PRR uses the drug serious report total and the term global serious total (N_serious=11,882,979); strata shown only when n ≥ 20
Seriousness and sex counts from openFDA count=serious, patient.patientsex, seriousnessdeath

Page generated 2026-10-08. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.